A prospective, open-label, multicenter, single-arm, Phase III study evaluated the efficacy and safety of Hizentra ® , a 20% human IgG for subcutaneous administration, in 51 primary immunodeficiency patients over 40 weeks. Patients previously on intravenous or subcutaneous IgG were switched to weekly subcutaneous infusions of Hizentra ® at doses equivalent to their previous
Introduction
Primary immunodeficiency (PI) disorders with B cell dysfunction, such as common variable immunodeficiency (CVID), X-linked agammaglobulinemia (XLA) and autosomal recessive agammaglobulinemia (ARAG), predispose patients to recurrent infections [1] [2] [3] [4] [5] [6] [7] . The mainstay of treatment is replacement therapy with human polyvalent IgG. Intravenous IgG (IVIG) administration has hitherto been the gold standard for IgG therapy [8] [9] [10] [11] [12] [13] [14] . However, subcutaneous IgG administration (SCIG) is being increasingly used and, with the development of more concentrated preparations, has gained wide acceptance in many countries [15] [16] [17] [18] [19] [20] .
Hizentra ® (IgPro20, recently approved in the US) is a new 20% liquid product with high purity (≥98% IgG) and stability at 25°C for at least 24 months due to formulation with 250 mmol/ L L-proline [21] . Owing to the 20% IgG concentration, which is a technical improvement, and its low viscosity (14.7 ± 1.2 mPa•s), it can be infused at low infusion volumes and high infusion rates resulting in potentially shorter infusion times compared to 16% preparations. The Hizentra ® manufacturing process, developed for the purification of another preparation with similar formulation, the IVIG IgPro10 (Privigen ® ), fulfills currently accepted pathogen safety criteria [22] .
The study reported here evaluated for the first time the efficacy, tolerability, safety, and pharmacokinetics of Hizentra ® in patients with PI at doses equivalent to those given during previous therapy (IVIG or SCIG). The rationale for a dose-equivalent switch from previous therapy was based on the European experience showing that SCIG administered at doses equivalent to IVIG is sufficient to achieve comparable IgG trough levels in patients with PI. This approach is reflected in the European Medicines Agency (EMA) guidelines for development of SCIG preparations [23] . In contrast, studies conducted in the US aim at achieving an equivalent IgG exposure, measured by the area under the concentration/time curve (AUC) of serum IgG, as requested by the US Food and Drug Administration (FDA) [20, 24] . The proof of concept of equivalent IgG doses has been tested in a study of Vivaglobin ® , a 16% SCIG product, which, administered at weekly subcutaneous doses equivalent to previous IVIG doses, resulted in IgG trough levels comparable to those with IVIG [19] .
Patients and methods

Patients
Males or females aged 2 to 65 years (16 to 65 years in the United Kingdom [UK] sites) with CVID or XLA, as defined by Pan-American Group for Immunodeficiency (PAGID) and European Society for Immunodeficiencies (ESID) [25] , or with ARAG were enrolled in the study. Patients should have received stable IVIG therapy at regular 3-or 4-week intervals or weekly SCIG therapy for at least 6 months before study start, at a monthly dose of 0.2 to 0.8 g/kg body weight (bw), with at least 3 documented serum IgG trough levels of ≥5 g/L. A chest X-ray or computed tomography (CT) scan obtained within 1 year prior to enrolment was required. Women of childbearing potential had to have a negative pregnancy test and use medically approved contraception. Patients participating in the pharmacokinetic substudy had to be at least 6 years old (at least 16 years old for sites in the UK).
Patients were excluded if they had never been treated with immunoglobulin replacement therapy, or had an ongoing serious bacterial infection (SBI) at the time of screening. Other exclusion criteria were malignancies of the lymphoid system, allergies or severe reactions to immunoglobulins and other blood products associated with high anti-IgA concentrations, hyperprolinemia, hypoalbuminemia, protein-losing enteropathies, significant proteinuria, treatment with steroids (oral or parenteral, ≥0.15 mg/kg/day of prednisone equivalent) or other systemic immunosuppressants, and any condition that was likely to interfere with evaluation of the study medication or satisfactory conduct of the study. Women who were pregnant, breast feeding, or planning a pregnancy during the course of the study were excluded as well.
This study was conducted in accordance with the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines, and the Declaration of Helsinki (version of 1996). The study protocol and all other studyrelated documents were reviewed and approved by the appropriate local Independent Ethics Committees. Written informed consent was obtained from all patients or patients' parents or legal guardians.
Study design
This was a prospective, open-label, multicenter, single-arm, Phase III study with a 12-week wash-in/wash-out period followed by a 28-week efficacy period ( Fig. 1) . A pharmacokinetic (PK) substudy was conducted in a subset of patients in Week 28 ± 1.
Treatment was initiated at a dose equivalent to the previous IVIG or SCIG dose, given once weekly. Dose adjustments were permitted during the wash-in/wash-out period if IgG trough levels were b 5 g/L. No further dose adjustments were permitted during the efficacy period, unless medically indicated.
Premedication taken on the same day prior to infusion to reduce AEs associated with SCIG infusion was not allowed. Oral and parenteral steroids were allowed if the average daily dose was b 0.15 mg of prednisone equivalent/kg/day. Local anesthetics could be used before infusion to reduce the pain associated with needle insertion if required.
Hizentra ® was administered subcutaneously using Crono PCA-50 or Super-PID infusion pumps (Cane S.R.L., Turin, Italy). One or more injection sites on the abdomen, thighs, and/or lateral hip could be used simultaneously and could be changed every week. The choice of infusion technique varied according to local practice, with patients already on SCIG treatment continuing with their established infusion technique. The initial volume per injection site was limited to 15 mL for patients switching from IVIG, with the possibility to be increased up to a maximum of 25 mL after the fourth infusion, depending on tolerability. Patients on SCIG could continue using the volume per injection site they had been used to, provided it did not exceed 25 mL. The total body infusion rate was not to exceed 25 mL/h during the wash-in/wash-out period and could be increased up to 35 mL/h during the efficacy period, depending on tolerability.
Patients were provided with a detailed description of the infusion technique. Three infusions at the beginning of the study were supervised and served as training for the patients or their parents/guardians. Infusions in Weeks 1, 2, 3 (for patients training in self-administration only), 4, 8, 12, 16, and 28 had to be performed at the study site under medical supervision. If a patient/parent/guardian was not able to perform home therapy after eight supervised infusions, the patient had to be discontinued from the study.
Efficacy and safety assessments
The primary efficacy endpoint was to compare descriptively IgG trough levels during 6 consecutive weeks at steady state (prior to Infusions 12 to 17) with 3 IgG trough levels from the patient's previous treatment (during the last 3 to 6 months prior to the study). Trough serum IgG levels were measured before Infusions 1, 4, 8, [12] [13] [14] [15] [16] [17] 20 and every fourth infusion thereafter. The last IgG trough level before the study start was the IgG trough level measured before the last intravenous infusion for patients previously on IVIG or the IgG trough level measured before Infusion 1 in this study for patients previously on SCIG. As the term "IgG trough level" has been defined to describe the lowest serum IgG level between two consecutive IVIG infusions, it is not considered appropriate in SCIG therapy, which maintains stable serum IgG levels, without "peaks" and "troughs". Although the term "IgG trough level" is widely used in subcutaneous IgG therapy (and, therefore, has been used in the study protocol as such), we refer to serum IgG concentrations measured before infusions as "IgG levels" further on in this manuscript.
Secondary efficacy endpoints included rate of clinically documented serious bacterial infections (SBIs), number of infection episodes, number of days missed from work/school/ kindergarten/day care or unable to perform normal activities due to infections (abbreviated further as number of days missed from work/school), number of days of hospitalization due to infections, and use of antibiotics for infection prophylaxis or treatment. Bacterial pneumonia, bacteremia/ septicemia, osteomyelitis/septic arthritis, bacterial meningitis and visceral abscess were considered SBIs and were diagnosed using pre-defined criteria adjusted to both adult and pediatric patients [26] .
The pharmacokinetic endpoints were AUC until the last measured concentration (AUC last ), maximal serum IgG concentration (C max ), and time to reaching C max (T max ). Blood samples were taken before Infusion 28, 10 ± 5 min prior to end of infusion, 2 ±1 h after infusion, and after 1, 2, 3, 4, and 7 days. Serum concentrations of L-proline and selected specific antibodies (anti-measles, anti-H. influenzae type B, antitetanus, and anti-S. pneumoniae polysaccharide antibodies) were determined as previously described [27] .
Patients evaluated their satisfaction with Hizentra ® treatment at baseline and at study end (defined as the last available observation) using the Treatment Satisfaction Questionnaire for Medication (TSQM) [28] . It includes 14 items, 13 of which are summarized in four domains ('Effectiveness', 'Side effects', 'Convenience' and 'Overall satisfaction') and 1 was rated as a separate question.
Information about AEs was collected continuously. Patients documented any findings in their diaries and Investigators transferred AEs into the Case Report Form (CRF) at visits. Local reactions at the infusion site were expected to occur due to the formation of a drug depot. For the analysis of local reactions, 25 preferred terms of the system organ class (SOC) category 'General disorders and administration site conditions' were combined in the category of local reactions. Local tolerability was assessed by the patients within 24 to 72 h after infusion and reviewed by the Investigators during visits.
Vital signs, including blood pressure, heart rate and body temperature, were evaluated at screening, and before and after each infusion administered at the study site. Clinical laboratory parameters were determined at screening, before Infusions 1, 4, 28, and at the Completion Visit. Direct Coombs' tests were performed at screening, before Infusions 16 and 28, and, in case of a positive result at Infusion 28, at the Completion Visit.
Statistical methodology
It was planned to enroll 36 patients, including 12 children aged b12 years, in approximately 12 centers, to achieve a sample size of 30 patients including at least 10 children evaluable for efficacy, tolerability, and safety. Of these patients, 18 were to be enrolled in the PK substudy in order to collect PK data of at least 15 patients. This sample size is consistent with EMA recommendations [29] .
Efficacy analyses were carried out on the intent-to-treat (ITT) population defined as all patients who were treated with Hizentra ® during the efficacy period. Safety analyses were carried out on the all-treated (AT) population defined as all patients who were treated with Hizentra ® during any study period. Pharmacokinetic analyses were carried out on the per-protocol pharmacokinetic (PPK) population that comprised all patients who had received uniformly repeated doses of Hizentra ® at weekly intervals during at least 12 weeks before Week 28 ± 1 and who provided blood sample series with not more than 3 missing samples or outliers in the AUC sampling period.
Descriptive statistics for continuous variables and frequency distributions for categorical variables were calculated with the SAS software package (SAS Institute, Cary, NC, USA), version 9.1.
For primary efficacy analyses, six consecutive steadystate IgG values were aggregated to the patient's median value. The same procedure was used for the three most recent IgG values ≥5 g/L on previous treatment. Median rather than mean values of the individual IgG levels were deemed better suited for comparing patients' serum IgG concentrations because of the high variation of the individual values.
In addition, all steady-state IgG values obtained in the efficacy period (before Infusions 12 to 17, 20, 24, 28, 32, 36, and 40) were used for calculation of the aggregated median values and compared with the IgG values on previous treatment.
The annual rate of SBIs per patient was estimated with 99% upper confidence limit (CL) using a Chi-Square distribution. The number of infection episodes was estimated with a two-sided 95% confidence interval (CI). No imputation was made for patients who discontinued the study.
AUC was obtained by the trapezoidal rule between the first and last IgG measurements [AUC last ], ignoring outliers.
Adverse events were coded using the Medical Dictionary for Regulatory Activities (MedDRA), version 12.0. Temporally associated AEs were defined as occurring between the start of infusion and 72 h after the end of infusion.
Results
Patients
Fifty-three Caucasian patients were screened at 15 study sites in Europe and 51 patients were enrolled in the study. Forty-six patients completed the wash-in/wash-out period and 43 patients completed the efficacy period ( Fig. 2 ), of whom 16 were under the age of 12. Twenty-four patients were included, and 23 completed the pharmacokinetic substudy.
The reasons for discontinuation were AEs (6 patients: 3 during the wash-in/wash-out period and 3 during the efficacy period) and withdrawal of consent (2 patients during the wash-in/wash-out period). More information about these AEs is provided below.
Patients' mean age was 21.5 years (Table 1) , including 17 children (b 12 years) and 5 adolescents (b16 years). The proportion of patients with XLA was high (n = 17) resulting in a two-fold higher proportion of males. The proportion of males and females with other diagnoses was similar. There were no significant differences between the ITT and the PPK populations with regard to demographic parameters and thus the PPK population could be considered a representative sample of all patients. Median duration of disease (since diagnosis) was 3.4 years for CVID and 7.2 years for XLA. The patient with ARAG had been diagnosed for 4 years.
Study drug administration
All 46 patients in the ITT population received the intended 12 infusions during the wash-in/wash-out period and 37 patients (80.4%) received the planned 40 infusions during the study.
The mean Hizentra ® dose per week was 118.7 mg/kg bw (range 117.0-120.7 mg/kg bw). The mean (SD) of individual median doses was 120.0 mg/kg bw (35.72) for the entire study, with similar values for the wash-in/wash-out period and the efficacy period. Dose adjustment during the wash-in/wash-out period was necessary in 7 patients, of whom 2 had a dose increase of N 10%, and 2 had a dose decrease of N 10%.
The total body infusion rate mean of medians was 25. 
Efficacy
Primary efficacy endpoint
Hizentra ® treatment resulted in serum IgG levels comparable to or higher than those achieved with previous therapy.
The pre-study IgG level mean of medians for all patients was 7.49 g/L ( Table 2) . The mean IgG level measured before Infusions 12 to 17 was 8.10 g/L. Thus, as the IgG levels on Hizentra ® were similar to those on previous therapy, the study objective was met. Nearly identical IgG values were obtained for the entire efficacy period ( Table 2) .
Before study start, the mean of individual median IgG values was higher in patients previously treated with SCIG (8.43 g/L) compared with patients previously treated with IVIG (6.78 g/L; Table 3 ). Thus, IgG levels with Hizentra ® were similar to pre-study levels with SCIG, but were higher by 17.7% than pre-study levels with IVIG of equivalent dose.
Pharmacokinetic parameters
Weekly administration of Hizentra ® treatment resulted in stable IgG levels in children and adults.
As expected for steady-state concentrations, changes in serum IgG concentrations during one dosing interval (Week 28 ± 1) were small: mean values measured throughout Week 28 ranged between 7.44 and 7.98 g/L (Fig. 3 ). The mean maximum serum IgG concentration (C max ) of 8.26 g/L was achieved after 2.06 days (mean T max ). The mean AUC last was 53.70 g·day/L. At the end of this dosing interval (7 days after the Week 28 infusion), the mean serum concentrations of selected specific antibodies were higher than those considered protective: antimeasles antibodies, 1.14 IU/mL (recommended level, 0.24 IU/mL [30] ); anti-H. influenzae type B antibodies, 1.92 mg/L (recommended level, 1 mg/L [31] ); anti-tetanus antibodies, 2.31 IU/mL (recommended level, ≥ 0.1 IU/mL [32] ); except for total anti-S. pneumoniae antibodies, 43.33 mg/L (recommended level N 40-70 mg/L depending on center).
The mean serum L-proline concentration was 259.8 μmol/L (SD 95.75 μmol/L) prior to the infusion during Week 28. The mean serum level increased to 370.3 ± 105.79 μmol/L 10 min prior to the end of the infusion and returned to pre-infusion level within 2 days after infusion (357.1 ± 99.60 2 h after infusion, 270.9 ± 84.25 after 1 day, and 252.0 ± 70.44 after 2 days). The normal serum concentration of L-proline is 266 ± 35 μmol/L [33] . Therefore, no evidence of L-proline accumulation in the circulation was observed.
Secondary efficacy endpoints
Hizentra ® was effective in maintaining the rate of infections to a low level. No SBIs were observed in this study during the efficacy period (rate 0 events/patient/year; upper 99% CL 0.192; Table 4 ). One patient had an SBI of X-ray proven pneumonia during the wash-in/wash-out period resulting in a rate of 0.03 events/patient/year for the full evaluation period in the ITT population (upper 99% CL 0.192).
During the efficacy period, 36 patients (78.3%) experienced an infection (rate 5.18 infections/patient/year, 95% CI 4.305, 6.171; Table 4 ). The most frequent type of infection was cough (16 events), followed by upper respiratory tract infection and bronchitis (15 events each).
Twenty patients (43.5%) missed work/school on a total of 198 days and 4 patients (8.7%) were hospitalized due to infections for a total of 86 days (Table 4 ). These results are significantly affected by input from a single patient, a 5-year old girl who experienced 3 serious AEs (SAEs) resulting in 71 days missed from school (details are provided in the section Serious adverse events) and 63 days spent in hospital. Because this experience differed markedly from that of the other patients in the study, a post-hoc analysis excluding this patient's data was performed. The results of this analysis showed a decrease in the number of all infections from 124 to 121, and in the rate of all infections from 5.18 to 5.16 infections/patient/year. Notably, the number of missed work/school days and days of hospitalization was reduced from 198 to 127 and from 86 to 23, respectively, with a corresponding reduction in rates from 8.00 to 5.25 days/patient/year and from 3.48 to 0.95 days/patient/ year, respectively (Table 4) .
Thirty-two patients (69.6%) were treated with antibiotics on 1743 days (Table 4 ). Antibiotics were used for prophylaxis in 4 patients (8.7%; 297 days), and for the treatment of adverse events, in 29 patients (63.0%; 873 days). In addition, 7 patients (15.2%) were treated with antibiotics for surgical or other current conditions on 691 days. Surgical or other current conditions treated with antibiotics included recurrent or chronic bronchitis, minor hemoptisis, bronchiectasis, pulmonary emphysema, acne, recurrent urine infection, common cold, recurrent folliculitis, recurrent or chronic sinusitis and abnormal lung X-ray. The median duration of antibiotics treatment was 23 days. In these patients, prolonged use of antibiotics (N 100 days) was required only for prophylaxis or for the treatment of surgical or other current conditions, except in the 5-year old patient who was treated for pneumonia with azithromycin for 116 consecutive days.
In order to investigate the difference in efficacy between patients previously treated with IVIG or SCIG, a post-hoc analysis of the efficacy endpoints by previous therapy was performed ( Table 5 ). The mean age of patients previously treated with IVIG or SCIG was similar (24.3 years and 23.1 years, respectively), as was the number of children aged b12 years (8 and 6, respectively). Most endpoints were lower in patients previously treated with IVIG than in those previously on SCIG, particularly when excluding the patient with recurrent pneumonia. Thus, patients previously on IVIG had a lower rate of all infections in this study (3.35 ) than those previously on SCIG (7.48). Fewer days on antibiotics were reported in patients previously on IVIG (53.09) compared to those on SCIG (83.87), with use for both prophylaxis and treatment of AEs being lower, while use for other medical conditions was similar. The same was true for rates of missed 46) . b Includes SBIs. The total number of days in the study was 4985 for patients previously on IVIG, and 3760 for patients previously on SCIG. c The total number of days from patient diaries was 5144 for patients previously on IVIG, and 3889 for patients previously on SCIG. d Data excluding the patient who suffered from recurrent pneumonias (previous therapy: IVIG). The total number of days in the study in this analysis was 4792 for patients previously on IVIG and 3760 for patients previously on SCIG. The total number of days from patient diaries in this analysis was 4944 for patients previously on IVIG, and 3889 for patients previously on SCIG.
work/school days. Considering that the mean weekly IgG doses during the last 9 months before this study were 131.5 mg/kg for previous IVIG therapy (mean of medians; SD 50.00) and 107.0 mg/kg for previous SCIG therapy (mean of medians; SD 28.54), these results suggest a tendency for dose dependence of the efficacy outcomes. However, the small sample size does not allow a meaningful statistical comparison of the data.
Patients previously treated with IVIG rated SCIG therapy with Hizentra ® as more convenient: the median TSQM domain score for 'Convenience' was 83.3 at study end vs. 55.6 at baseline. The median change of 33.3 points was statistically significant (95% CI 22.2, 38.9). In the other TSQM domains, there was slight or no improvement for patients previously on IVIG. Little or no change was observed in patients switching from SCIG.
Safety and tolerability
Local reactions
Local tolerability results showed that patients tolerated Hizentra ® administration well. Local reactions are common with SCIG administration. In this study, 25 patients (49.0%) experienced 110 local reactions (rate 0.060 per infusion). The proportion of patients reporting local reactions decreased over time: approximately 20% of patients reported local reactions after the first infusion, but the proportion of patients experiencing local reactions decreased after the subsequent infusions, with only b 5% of patients reporting local reactions for 24 of the 29 infusions during the efficacy period. Overall, 1699 of the 1831 infusions (92.8%) were tolerated without any local reactions (Fig. 4) . Most (87.3%) of local reactions were mild in intensity, 11.8% were moderate, and only 1 (0.9%), an injection site pruritus, was severe.
Patients evaluated their overall local tolerability as 'good' or 'very good' for 1767 (96.5%) infusions. Rating of 'fair' was reported for 52 (2.8%) infusions, most of them (65.4%) during the wash-in/wash-out period; rating of 'poor' local tolerability was reported for 6 (0.3%) infusions only. These results are in agreement with the frequency of observed local reactions (only 20% of patients experienced local reactions after the first infusion). However, contrary to the observed decrease in the occurrence of local reactions, no clear trend in patients' tolerability assessments over time was observed, probably due to the low number of 'fair' and 'poor' ratings. Two of the 5 patients who rated local tolerability as 'poor' after one infusion had assessed it as 'good or very good' after the previous and subsequent infusions; the other 3 patients discontinued the study due to AEs, including local reactions in 2 patients with history of injection site reaction or urticaria.
Overall adverse events
Including local reactions, 50 patients (98.0%) had at least 1 AE, and, overall, 527 AEs occurred during a total of 1831 infusions, resulting in an AE rate of 0.288 per infusion. Apart from local reactions, the most common AEs were infections of the respiratory tract and headache ( Table 6) .
Temporally associated AEs (72 h) occurred in 48 patients (94.1%). A total of 324 AEs were reported (0.177 AEs/infusion), the most common being local reactions, followed by headache and infections of the respiratory tract (Table 6 ). Thus, the type and incidence of temporally associated AEs reflected closely those of all reported AEs.
Overall, 194 AEs experienced by 31 patients (60.8%) were considered related to Hizentra ® administration (0.106 AEs/ infusion). The most common related AEs were headache and pruritus, with pruritus being also the most frequent temporally associated AE (Table 7) .
Almost all (98.7%) AEs were mild or moderate in intensity. Seven severe AEs-chest pain, injection site pruritus, appendicitis, bronchitis, pneumonia, increased C-reactive protein, and cough-occurred only once, in 6 patients. Pneumonia and appendicitis were SAEs, and chest pain and increased C-reactive protein led to discontinuation; more information on these two AEs is provided in the following sections.
Serious adverse events
Five patients (9.8%) experienced 7 SAEs, none of them related to the study medication. The SAEs were diarrhea, pneumonia (2 events), pyrexia, bronchiolitis, appendicitis, and sciatica. Two of them (pneumonia and appendicitis) were severe and 1 (diarrhea) was mild in intensity. All but one SAE resolved without sequelae; the event of sciatica resolved with sequelae (acute lumboischialgia had resolved; recurrent ischialgia was ongoing). The patient completed treatment as planned.
A 5-year old girl with CVID suffered from recurrent pneumonias and spent markedly more days in hospital and on antibiotic treatment than the other patients in the study. She had a complex medical history including recurrent severe pneumonia flares requiring hospitalization on several occasions from 2007, and suffered from a number of serious co-morbidities (atopic dermatitis, varicella, chronic pneumonia, mononucleosis syndrome, and recent Enterococcus, Enterobacter and Candida albicans infections). This was the patient excluded from the post-hoc analysis performed to evaluate the efficacy in patients with less severe disease. She experienced 3 SAEs: 1 event of pyrexia and 2 events of X-ray proven pneumonia (one of them, occurring in the washin/wash-out period, was classified as an SBI according to the pre-specified FDA criteria). The first event of pneumonia was moderate in intensity and was considered an SBI because chest X ray/CT scan showed distinctive nodular and new infiltrative changes of both lungs, despite negative sputum and blood cultures. Approximately a month later, when the patient was hospitalized for diagnostic purposes, bronchoalveolar lavage was positive for atypical mycobacteria (only in polymerase chain reaction test). Tests for Mycobacterium tuberculosis were negative. This SBI resolved after 34 days without sequelae. Four days after Infusion 14, during the efficacy period, the patient experienced pyrexia that was reported as an SAE of moderate intensity; the event resolved within 2 days without sequelae. Four days after Infusion 22, the patient experienced pneumonia that was reported as an SAE of severe intensity. She had fever and cough, and her laboratory tests were indicative of an ongoing inflammatory process (white blood cells 25.69× 10 9 ; C-reactive protein 31.8 mg/L; hemoglobin 9.7 g/dL; ALT 13.1 U/L). The episode was ongoing at the final assessment. Because of the underlying lung disease and medical history of persistent pneumonia, this event was an acute exacerbation of the existing pneumonia, and thus not considered an additional SBI. The patient completed the study as planned. However, despite major medical intervention and continuous SCIG treatment, her general condition deteriorated and she died from respiratory failure two months later.
No deaths occurred during the study.
Adverse events leading to discontinuation
A combination of 14 AEs led to discontinuation of 6 patients (11.8%). Seven AEs, 4 of them local reactions, in 3 patients were considered related to Hizentra ® administration: injection site pain, injection site pruritus, injection site reaction (2 events), fatigue, feeling cold, and hypersensitivity. These resolved without sequelae.
Laboratory tests
Median values and ranges of hematology and serum chemistry variables did not show any relevant changes over time. All individual hematology, blood chemistry and urinalysis values lying outside the normal range were considered by the investigator not clinically significant.
Direct Coombs' test
There was no evidence of hemolysis during this study, as evidenced by measurements of hemoglobin and reticulocytes. One patient, who had a negative direct Coombs' test at screening, had a positive Coombs' test at the completion visit after Infusion 9. His hemoglobin values were stable and within normal range (between 15.0 and 15.8 g/L). The patient discontinued the study after Infusion 9 due to AEs of injection site reaction, fatigue, and feeling cold. Four patients had positive direct Coombs' tests at screening and throughout the study.
Discussion
This is the first study of Hizentra ® treatment in patients with PI at doses equivalent to those in previous therapy. The results showed that Hizentra ® is effective in protecting from serious and non-serious infections and is well tolerated by patients with PI in all age groups.
The primary objective of this study, achievement of sustained IgG levels at equivalent doses compared with previous IVIG or SCIG therapy, was met. IgG levels with Hizentra ® were similar or higher than those on previous therapy. In particular, results in patients switched from another SCIG to Hizentra ® showed that IgG levels were comparable and thus the bioavailability of different SCIG products was similar. IgG levels in patients switching from IVIG, on the other hand, increased by 17.7% with Hizentra ® treatment, probably due to the more frequent, weekly, administration of the monthly equivalent IVIG dose split into smaller doses. As a result, the wear-off effect of low IgG levels typical for IVIG administration could be averted. Thus, switching to Hizentra ® treatment from any previous IgG treatment regimens can be accomplished without compromising serum IgG levels.
In this study, patient evaluation of treatment satisfaction with Hizentra ® was performed for the first time. The results showed a significant improvement from baseline to study end in the domain 'Convenience' in patients switching from IVIG and sustained treatment satisfaction in patients switching from SCIG, suggesting favorable effects on patients' quality of life.
Hizentra ® could be administered conveniently using 2 or 3 sites consecutively, or 2 pumps simultaneously, resulting in reasonably short infusion times (individual median infusion durations between 1.14 and 1.27 h). Up to the maximal pump rate, no decreases in infusion rates due to pump backpressure were reported.
Efficacy results in patients previously treated with IVIG or SCIG were markedly different, yet it was not possible to establish a clear association with dose due to the small sample size of the respective subgroups. Rates of infections, antibiotic use and missed work/school days were lower in patients previously treated with IVIG compared with those previously on SCIG, while days in hospital were similar. As IgG doses in this study were equivalent to previous treatment doses, patients previously on IVIG were administered generally higher weekly doses than those previously on SCIG (mean doses 131.5 and 107.0 mg/kg, respectively). These results suggest a moderate improvement in infection rates with higher dose, but a much larger sample size would be required to evaluate a possible dose effect on clinical outcomes.
This study also provides data for comparison with the efficacy results of the US registration study of Hizentra ® [24] . The two studies differ mainly in the initial dose and the different indicators for dose adjustment: while dose-equivalent switch from IVIG therapy was chosen in this study according to the clinical practice in Europe, an equivalence of AUC was aimed at in the US study per FDA guidelines, resulting in mean doses of 153% the previous IVIG dose during the efficacy period. The mean weekly doses in the US study were 176.8-224.3 mg/kg bw compared with 59-243 mg/kg bw in this study. A direct consequence of the higher doses in the US study was the higher mean IgG level achieved: 12.1-12.9 g/L [24] compared with 7.99-8.25 g/L in this study. In keeping with the general agreement that higher levels ensure better protection, several efficacy endpoints were more favorable with higher IgG levels. For example, while the rate of SBIs was similar in the two studies, the rate of non-serious infections was lower in the US study compared with this study (2.76 vs. 5.18 infections/patient/year, respectively) [24] . A similar relationship was observed for days missed from work/school (2.06 in the US study vs. 8.00 in this study), days spent in hospital due to infection (0.2 vs. 3.48, respectively) and use of antibiotics (48.5 vs. 72.75, respectively). These results might be biased by the severe disease of the patient with recurrent pneumonias, as well as the higher number of children in the European study. The rate of infections in young children is higher than in adults, and the threshold for children missing school may be different from that for adults missing work. In addition, cultural and/or economical differences between Europe and the US may contribute to the difference in the number of days missed from work/school and days with hospitalization.
The impact of almost two-fold higher doses of Hizentra ® administered in the US study on the difference in annualized infection rates cannot be ruled out. However, several factors may have influenced the observed difference in infection rates. Only the diagnostic criteria for SBIs were uniformly defined in the two study protocols. Diagnosis of all other infections was at investigator's discretion and according to the national standard of medical practice, including different diagnostic approaches to infections in various countries. Therefore, comparing infection rates from different countries must be performed with caution. In published SCIG studies, definition and reporting of infections differ substantially due to differences in the study populations, assessment methods, statistical analyses, particularly the calculation of infection rates [34] [35] [36] . In this and the US study, any symptom or sign of infection diagnosed by a participating investigator according to their national standard of care and reported as an AE, was counted as an infection, in order to ensure collection of complete information about any infections patients experienced in the studies. Given the small sample size, the distribution of individual infection types may vary between the two studies, contributing to the difference in rates.
The concentrations of specific antibodies were also different in the two studies. The serum levels of anti-H. influenzae and anti-tetanus antibodies were 1.5-2-fold higher in the US study patients (3.32 mg/L and 4.65 IU/mL, respectively, at the end of the weekly dosing interval [27] ), corresponding to the higher dose administered. However, a disproportionately higher level (compared to the IgG dose increase) of anti-S. pneumoniae (3-4-fold higher than in the EU study) was observed in the US study (mean 140.02 mg/L [27] ). It may be possible that the higher level of anti-S. pneumoniae antibodies could be relevant for the lower frequency of infections observed in the US study. Patients entered the two studies with their IgG doses individually adjusted during previous treatment to keep their infection rate to the acceptable minimum. Therefore, their doses to a large extent represented the severity of their PI conditions. The studies were not designed to evaluate the dose-outcome relationship on a continuous scale. Due to the relative rarity of PI conditions, clinical studies of IgG preparations usually have sample sizes similar to those used in the two Hizentra studies, which, taken alone, are not powered to answer this question.
Even taking into account the sources of potential bias and the fact that the studies were not designed to evaluate outcomes in relation to dose, the results corroborate previous findings supporting improved outcomes with higher doses of immunoglobulin. The optimal dose and IgG level in antibody deficiency are likely to vary between individuals in differing clinical settings, but the results from this and the US Hizentra ® study underline the importance of high serum IgG concentrations for protection from infections. IgG levels higher than 7 g/ L, which are in the normal range for healthy individuals [37, 38] , have been shown to be associated with better clinical outcomes, if not necessarily with reduced rate of infections [36, [39] [40] [41] . A further question about SCIG therapy is whether subcutaneous doses higher than intravenous doses (resulting from the AUC matching concept) are necessary and/or meaningful for switching to SCIG.
This study would suggest that the switch from IVIG to SCIG therapy does not require an increase in dose to maintain either serum IgG levels or a similar clinical outcome with regard to severe infections. However, regarding the separate question as to the optimal dose and IgG level, information from this and the US study supports the increasingly convincing case that higher IgG levels than those attained with the currently recommended doses (400-600 mg/kg/month)-with either IVIG or SCIG therapy-minimize the frequency of serious and non-serious infections. Further studies are needed to define whether a higher IgG dose yields benefits in terms of end organ damage such as bronchiectasis. Standardized and detailed reporting of clinical outcomes would be necessary to compare studies and further evaluate the issue.
The efficacy results reported here offer reassurance that PI patients treated with replacement therapy are well protected from the burden of recurrent infections to a degree consistent with sustained health. Thus, similar IgG levels and similar data for days missed from work/school and days on antibiotics have been reported with several IVIG preparations [14, [41] [42] [43] . Our results corroborate also previously reported data for Vivaglobin ® , a 16% SCIG, [16, 19, 20] suggesting that IVIG and SCIG preparations show similar efficacy.
Patients tolerated Hizentra ® treatment well, with local reactions mostly mild and moderate in intensity. Moreover, the rate of local reactions decreased with ongoing use to an extent that, for a period of 7 weeks in the second half of the study, no local reactions were reported. Related systemic AEs such as headache and fatigue were infrequent and of mild or moderate intensity. None of the SAEs was related to the study medication. Historical infections may have resulted in end organ damage in the patient with recurrent pneumonias who experienced several severe AEs. The clinical course in this patient serves to underline the severity of the potential consequences of PI and the challenges for the optimal treatment of this group of patients.
Self-administration was accepted well, as evidenced by the few discontinuations (8 patients, 15.7%). As many as 21 pediatric patients completed the study, suggesting that therapy was well tolerated and fitted with their daily activities.
In conclusion, following a dose-equivalent switch from previous IVIG or SCIG therapy, Hizentra ® is effective in maintaining or increasing IgG levels and in protecting PI patients from infections, and is well tolerated. The short infusion duration and lack of severe local reactions favor self-administration.
